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STUDY OF SERUM FIBROBLAST GROWTH FACTOR- 23 (FGF23) LEVELS 
IN CHRONIC KIDNEY DISEASE 
BACKGROUND: 
Chronic kidney disease (CKD) is a major public health problem all over the world 
leading to poor outcomes like End Stage Renal Disease (ESRD), Cardio Vascular 
Disease (CVD) and Premature Death. 
Fibroblast growth factor (FGF)-23 is a recent phosphatonin secreted by the 
osteocytes acting as a key regulator of phosphate homeostasis. It initiates secondary 
hyperparathyroidism in patients with CKD. Serum FGF-23 levels rise progressively as 
renal function declinesand  serumFGF-23is an independent predictor of  CKD 
progression.  
AIMS AND OBJECTIVES:  
To evaluate the role of  FGF23 as an early marker of CKD – MBD and to estimate 
serum FGF-23 levels in CKD cases and healthy (age and sex matched)controls. 
MATERIALS AND METHODS: 
This cross-sectional study was conducted at MGMGH, Trichy. 45 CKDcases and  
45  healthy controls were selected for the study who were of  20-75 years of  age. CKD is 
divided into 5 stages as per NKF-K/DOQI Classification. 
Serum analyses of FPG, Serum Urea, Creatinine,Uric acid, Albumin, Sodium, 
Potassium, Calcium, Phosphate,  ALP,FGF23, Urine albuminand USG Abdomenwere 
done. eGFR  calculatedusing CKD-EPI formula.Student  t-test, ANOVA and Pearson’s 
correlation coefficient were used for the statistical analysis. 
RESULTS AND DISCUSSION: 
There was a statistically significant difference in serum FGF-23 levels between 
cases (mean 730.70 ± 492.72) and controls (mean 39.49 ± 12.47).With decreasing eGFR 
in CKD, serum FGF23 levels increase prior to increasing serum phosphate. Serum 
FGF23 levels increase as early as stage2 of CKD. The difference in mean serum FGF-23 
levels, serum phosphate between various eGFR groups were statistically significant 
(p<0.05) among the cases. 
CONCLUSION: 
FGF23 is involved in mineral metabolic disorders implicated in CKD-MBD. 
Serum FGF23 levels were significantly increased in patients with CKD prior to increase 
in serum phosphate levels and serum FGF23 levels increase progressively from early to 
late stages of CKD. Higher the serum FGF23, more severe is the disease. Serum FGF23 
may thus be considered as an early marker of progression of CKD. 
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